Gross Profit Comparison: United Therapeutics Corporation and Viatris Inc. Trends

Pharma Giants' Profit Trends: A Decade in Review

__timestampUnited Therapeutics CorporationViatris Inc.
Wednesday, January 1, 201411626360003669400000
Thursday, January 1, 201513967250004382200000
Friday, January 1, 201615261000004998500000
Sunday, January 1, 201716196000004976200000
Monday, January 1, 201814291000004572000000
Tuesday, January 1, 201913312000004444200000
Wednesday, January 1, 202013752000003796700000
Friday, January 1, 202115630000005575500000
Saturday, January 1, 202217896000006497000000
Sunday, January 1, 202320700000006438600000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: United Therapeutics vs. Viatris

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, United Therapeutics Corporation and Viatris Inc. have shown distinct trajectories in their gross profit margins. From 2014 to 2023, Viatris Inc. consistently outperformed United Therapeutics, with gross profits peaking at approximately $6.5 billion in 2022, a 77% increase from 2014. Meanwhile, United Therapeutics saw a steady rise, culminating in a 78% increase to $2.07 billion in 2023. This growth reflects strategic advancements and market positioning. Notably, both companies experienced a dip in 2018, highlighting industry-wide challenges. As we look to the future, these trends offer valuable insights into the competitive landscape and financial health of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025